Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance programs into the clinic. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term.
Our goal is to operate a wholly owned genomic medicine pipeline, which we fund via our collaborations with blue chip pharma partners, which have already brought in $815M in upfronts and milestones with $7B in potential bio bucks. We believe that manufacturing is a strategic advantage and gives us greater control over timelines, quality and supply. Our strong balance sheet enables us to execute and deliver on our mission.
7000 Marina Blvd, Brisbane, CA 94005
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Week of September 20, 2021
|Date Requested||Closing Price||Volume||Split Adjustment Factor||Open Price||Day High||Day Low|
|September 20, 2021||$9.28||914,663||1:1||$9.28||$9.50||$9.15|
|September 21, 2021||$9.54||873,355||1:1||$9.34||$9.61||$9.31|
|September 22, 2021||$9.60||713,254||1:1||$9.62||$9.66||$9.46|
|September 23, 2021||$9.83||725,212||1:1||$9.62||$9.83||$9.51|
|September 24, 2021||$9.60||676,611||1:1||$9.70||$9.81||$9.54|